verified99%+ Verified Purity
local_shippingFast EU Delivery (through resellers)
Myotrope
Homechevron_rightAll Peptideschevron_rightRetatrutide Injection Pen
Retatrutide Injection Pen
verified_user

Safety data sheet

Standardized safety protocols and material specifications for professional use.

analytics

Certificate of Analysis

Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-retatrutide-injection-pen-15mg

Official Product Data Sheet

Retatrutide Injection Pen (15mg)

High >98% Purity

Vial Contents
15 mg Retatrutide (3 mL pre-filled injection pen)
Includes
Ready-to-use multi-dose injection pen — no mixing required
Form
Pre-filled multi-dose pen
Purity
≥98%, third-party verified
Sequence
Triple Agonist (GLP-1/GIP/Glucagon)
Molecular Formula
See chemical properties
Molecular Mass
≈4731 g/mol
CAS No.
2381089-83-2
Solubility
Concentration: 5 mg/mL | Per click: 1 unit = 50 mcg
Storage
Refrigerate at 2–8 °C. Protect from light. Do not freeze.

Authorized Resellers

Available through our trusted partners

12
verifiedVerified

123peptide.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new
DE
verifiedVerified

Depeptidenwinkel.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new
View all authorized resellersshopping_cart
swipe_rightSwipe to see all tabs

Scientific Background

Retatrutide is an advanced triple GLP-1/GIP/glucagon receptor agonist with up to 28.7% weight reduction in Phase 3 trials. The 15 mg pen at 5 mg/mL provides 50 mcg per click — enabling precise titration from 1–3 mg/week with excellent per-pen economy compared to the 10 mg format.

Intended Research Use

  • Triple receptor activation at mid-range dose protocols
  • Appetite suppression and energy expenditure studies
  • Extended duration metabolic research
  • Dose-escalation research from 1–3 mg/week range

menu_bookScientific Publications

article

N Engl J Med (2023)

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/37366315/

article

Lancet (2023)

Retatrutide for Type 2 Diabetes

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/37364343/

warning

FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.

Myotrope

Possible stacks with other peptides

Synergistic combinations for enhanced research outcomes

Retatrutide pairs well with complementary metabolic and regenerative peptides.

GLOW Blend 70mg

GLOW Blend 70mg (70mg vial)

arrow_forward

myo-glow-blend-70mg

Reduce GI side-effects and add skin/recovery benefits alongside Retatrutide's metabolic action.

Cagrilintide 5mg

Cagrilintide 5mg (5mg vial)

arrow_forward

myo-cagrilintide-5mg

Complementary amylin-pathway satiety amplifying triple-receptor appetite suppression.

schedule

Cycling Note: Titrate every 4 weeks. Extended protocols of 12–52 weeks are typical.

Also Available

Retatrutide 10mg
Vial

Retatrutide

10mg

Retatrutide 15mg
Vial

Retatrutide

15mg

Retatrutide 20mg
Vial

Retatrutide

20mg

Retatrutide Injection Pen 10mg
Pen

Retatrutide Injection Pen

10mg

Retatrutide Injection Pen 20mg
Pen

Retatrutide Injection Pen

20mg

Retatrutide Injection Pen 30mg
Pen

Retatrutide Injection Pen

30mg

Retatrutide Injection Pen 60mg
Pen

Retatrutide Injection Pen

60mg